AtriCureATRC
Market Cap: $1.41B
About: AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
Employees: 1,200
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
94% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 51
59% more call options, than puts
Call options by funds: $2.94M | Put options by funds: $1.85M
1.05% less ownership
Funds ownership: 105.77% [Q1] → 104.71% (-1.05%) [Q2]
12% less funds holding
Funds holding: 221 [Q1] → 195 (-26) [Q2]
25% less capital invested
Capital invested by funds: $1.53B [Q1] → $1.15B (-$376M) [Q2]
49% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 53
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
BTIG Marie Thibault 86% 1-year accuracy 6 / 7 met price target | 83%upside $53 | Buy Maintained | 31 Jul 2024 |
JP Morgan Robbie Marcus 50% 1-year accuracy 10 / 20 met price target | 3%upside $30 | Overweight Maintained | 31 Jul 2024 |
Stifel Rick Wise 57% 1-year accuracy 16 / 28 met price target | 10%downside $26 | Buy Maintained | 31 Jul 2024 |
Needham Mike Matson 61% 1-year accuracy 69 / 114 met price target | 17%upside $34 | Buy Maintained | 31 Jul 2024 |
Piper Sandler Matt O'Brien 49% 1-year accuracy 22 / 45 met price target | 38%upside $40 | Overweight Maintained | 31 Jul 2024 |